Clinical practice guidelines for diagnosis, treatment, and follow-up of patients with mantle cell lymphoma. Recommendations from the GEL/TAMO Spanish Cooperative Group

[1]  K. Lakshmaiah,et al.  Primary Gastrointestinal Mantle Cell Lymphoma: A Retrospective Study , 2014, Journal of Gastrointestinal Cancer.

[2]  M. Stauch,et al.  Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial , 2013, The Lancet.

[3]  A. Rosenwald,et al.  CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell lymphoma. , 2013, Blood.

[4]  G. Salles,et al.  CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte. , 2013, Blood.

[5]  Michael L. Wang,et al.  Interim Results of an International, Multicenter, Phase 2 Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory Mantle Cell Lymphoma (MCL): Durable Efficacy and Tolerability with Longer Follow-up , 2012 .

[6]  R. Advani,et al.  Mature Results From ECOG Study E1405 – A Phase II Study of VcR-CVAD with Maintenance Rituximab for Previously Untreated Mantle Cell Lymphoma , 2012 .

[7]  P. Hokland,et al.  A highly sensitive and specific qPCR assay for quantification of the biomarker SOX11 in mantle cell lymphoma , 2012, European journal of haematology.

[8]  E. Giné,et al.  Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. , 2012, Cancer research.

[9]  A Orfao,et al.  EuroFlow: Resetting leukemia and lymphoma immunophenotyping. Basis for companion diagnostics and personalized medicine , 2012, Leukemia.

[10]  W. Klapper,et al.  Treatment of older patients with mantle-cell lymphoma. , 2012, The New England journal of medicine.

[11]  A Orfao,et al.  EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes , 2012, Leukemia.

[12]  B. Sander,et al.  Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma. , 2012, Blood.

[13]  B. Cheson,et al.  Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909 , 2012, Haematologica.

[14]  E. Giné,et al.  Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease , 2012, Leukemia.

[15]  S. Pileri,et al.  Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers , 2012, Haematologica.

[16]  R. Warnke,et al.  In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior , 2012, Haematologica.

[17]  H. Tilly,et al.  Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT). , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  G. Hess,et al.  Effect of Prognostic Risk Classification on Temsirolimus Efficacy and Safety Outcomes in Patients with Relapsed/Refractory Mantle Cell Lymphoma , 2011 .

[19]  M. Dreyling,et al.  Temsirolimus in Combination with Bendamustine and Rituximab for the Treatment of Relapsed Mantle Cell and Follicular Lymphoma: Report on An Ongoing Phase I/II Trial , 2011 .

[20]  D. Maloney,et al.  Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  R. Lai,et al.  Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis , 2011, Haematologica.

[22]  A. Chott,et al.  Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma , 2011, Haematologica.

[23]  P. Evans,et al.  Indolent mantle-cell lymphoma: immunoglobulin variable region heavy chain sequence analysis reveals evidence of disease 10 years prior to symptomatic clinical presentation. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Elias Campo,et al.  The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. , 2011, Blood.

[25]  N. Schmitz,et al.  Patterns and outcome of relapse after autologous stem cell transplantation for mantle cell lymphoma , 2011, Cancer.

[26]  A. Feldman,et al.  Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. , 2011, The Lancet. Oncology.

[27]  P. Korkolopoulou,et al.  Combination of rituximab with chlorambucil as first line treatment in patients with mantle cell lymphoma: a highly effective regimen , 2011, Leukemia & lymphoma.

[28]  Peter Martin,et al.  Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  M. Aapro,et al.  Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  T. Habermann,et al.  A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma , 2010, Leukemia.

[31]  M. Stauch,et al.  Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab In Patients with Relapsed Follicular, Indolent and Mantle Cell Lymphomas – Final Results of the Randomized Phase III Study NHL 2–2003 on Behalf of the StiL (Study Group Indolent Lymphomas, Germany) , 2010 .

[32]  W. Klapper,et al.  R-CHOP/R-DHAP Compared to R-CHOP Induction Followed by High Dose Therapy with Autologous Stem Cell Transplantation Induces Higher Rates of Molecular Remission In MCL: Results of the MCL Younger Intergroup Trial of the European MCL Network , 2010 .

[33]  F. Bosch,et al.  Rituximab Plus Gemcitabine and Oxaliplatin as Salvage Therapy In Patients with Relapsed/Refractory Mantle-Cell Lymphoma. , 2010 .

[34]  C. Craddock,et al.  Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[35]  Michael L. Wang,et al.  Phase I trial of bortezomib in combination with rituximab‐HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma , 2010, British journal of haematology.

[36]  J. Winter,et al.  Management of mantle cell lymphoma: key challenges and next steps. , 2010, Clinical lymphoma, myeloma & leukemia.

[37]  E. Steyerberg,et al.  Validation, revision and extension of the Mantle Cell Lymphoma International Prognostic Index in a population-based setting , 2010, Haematologica.

[38]  J. Rossi,et al.  Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group , 2010, Haematologica.

[39]  C. Geisler.  Front-line treatment of mantle cell lymphoma , 2010, Haematologica.

[40]  Michael L. Wang,et al.  Ten‐year follow‐up after intense chemoimmunotherapy with Rituximab‐HyperCVAD alternating with Rituximab‐high dose methotrexate/cytarabine (R‐MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma , 2010, British journal of haematology.

[41]  R. Siebert,et al.  Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma , 2010, Genes, chromosomes & cancer.

[42]  W. Klapper,et al.  Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. , 2010, Blood.

[43]  J. Šmardová,et al.  Loss of the p53 tumor suppressor activity is associated with negative prognosis of mantle cell lymphoma. , 2010, International journal of oncology.

[44]  E. Kimby,et al.  The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). , 2010, Blood.

[45]  A. Rosenwald,et al.  Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. , 2010, Cancer research.

[46]  J. Byrd,et al.  Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  M. Ogura,et al.  Bendamustine Is Highly Effective for Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphoma (B-NHL) and Mantle Cell Lymphoma (MCL): Final Results of a Japanese Multicenter Phase II Study. , 2009 .

[48]  A. Salar,et al.  Feasability and Toxicity After Induction Treatment with Rituximab-HCVAD and Metotrexate/Citarabine, Followed by Consolidation with Y-90 Ibritumomab Tiuxetan (Phase II GELTAMO–LCM 04-02 study). , 2009 .

[49]  J. Delabie,et al.  (90)y-Ibritumumab Tiuxetan (Zevalin (R))-BEAM/C with Autologous Stem Cell Support as Frontline Therapy for Advanced Mantle Cell Lymphoma.- Preliminary Results From the Third Nordic MCL Phase II Study (MCL3) , 2009 .

[50]  L. Staudt,et al.  SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype , 2009, Haematologica.

[51]  M. Eriksson,et al.  Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  B. Coiffier,et al.  Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  Jeroen van der Laak,et al.  Ki-67 as a prognostic marker in mantle cell lymphoma—consensus guidelines of the pathology panel of the European MCL Network , 2009, Journal of hematopathology.

[54]  P. Barros-Núñez,et al.  Detection of clonal immunoglobulin and T-cell receptor gene recombination in hematological malignancies: monitoring minimal residual disease. , 2009, Cardiovascular & hematological disorders drug targets.

[55]  I. Lossos,et al.  Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma , 2009, British journal of haematology.

[56]  L. Medeiros,et al.  Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. , 2009, Blood.

[57]  J. Leonard,et al.  Outcome of deferred initial therapy in mantle-cell lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  Lei Wu,et al.  The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. , 2009, Microvascular research.

[59]  T. Barbui,et al.  High-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting in mantle cell lymphoma: a 10-year update of the R-HDS regimen , 2009, Bone Marrow Transplantation.

[60]  E. Hoster,et al.  Improvement of overall survival in advanced stage mantle cell lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  A. Hagenbeek,et al.  High‐dose Ara‐C and beam with autograft rescue in R‐CHOP responsive mantle cell lymphoma patients , 2009, British journal of haematology.

[62]  A. Skotnicki,et al.  Survival benefit of post induction consolidation therapy in MCL (mantle cell lymphoma): A Polish Lymphoma Research Group (PLRG) retrospective multicenter analysis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  W. Hiddemann,et al.  Current treatment standards and emerging strategies in mantle cell lymphoma. , 2009, Hematology. American Society of Hematology. Education Program.

[64]  J. Leonard,et al.  Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[65]  K. Kolibaba,et al.  Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma , 2009, Investigational New Drugs.

[66]  R. Kodet,et al.  Quantitative monitoring of cyclin D1 expression: A molecular marker for minimal residual disease monitoring and a predictor of the disease outcome in patients with mantle cell lymphoma , 2008, International journal of cancer.

[67]  E S Costa,et al.  A probabilistic approach for the evaluation of minimal residual disease by multiparameter flow cytometry in leukemic B‐cell chronic lymphoproliferative disorders , 2008, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[68]  F. Angrilli,et al.  Rituximab Plus Hypercvad Alternating with High Dose Methotrexate and Cytarabine for Patients with Newly Diagnosed Mantle Cell Lymphoma. A Multicenter Trial from GISL , 2008 .

[69]  Michael L. Wang,et al.  Phase 2 trial of rituximab plus hyper‐CVAD alternating with rituximab plus methotrexate‐cytarabine for relapsed or refractory aggressive mantle cell lymphoma , 2008, Cancer.

[70]  I. Lossos,et al.  Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  E. Kimby,et al.  Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. , 2008, Blood.

[72]  B. Sander,et al.  The subcellular Sox11 distribution pattern identifies subsets of mantle cell lymphoma: correlation to overall survival , 2008, British journal of haematology.

[73]  A. Tulpule,et al.  Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  Xianglin L. Du,et al.  Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004 , 2008, Cancer.

[75]  D. Moore,et al.  Low‐dose, single‐agent temsirolimus for relapsed mantle cell lymphoma , 2008, Cancer.

[76]  A. Tienhaara,et al.  Stem cell transplantation in poor‐risk chronic lymphocytic leukemia: assessment of post‐transplant minimal residual disease using four‐ and six‐color flow cytometry and allele‐specific RQ‐PCR , 2008, European journal of haematology.

[77]  M. Haber,et al.  Improving minimal residual disease detection in precursor B-ALL based on immunoglobulin-κ and heavy-chain gene rearrangements , 2008, Leukemia.

[78]  J. Leonard,et al.  Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[79]  J. Byrd,et al.  Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. , 2008, The Journal of clinical investigation.

[80]  E. Campo,et al.  Secondary genomic alterations in non-Hodgkin’s lymphomas: tumor-specific profiles with impact on clinical behavior , 2008, Haematologica.

[81]  W. Klapper,et al.  Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations , 2008, Haematologica.

[82]  Karin Jirström,et al.  From bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 28, 2013. For personal use only. , 2006 .

[83]  D. Moore,et al.  Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: A phase II trial in the North Central Cancer Treatment Group , 2008, Leukemia & lymphoma.

[84]  Jacques Corbeil,et al.  Bendamustine (Treanda) Displays a Distinct Pattern of Cytotoxicity and Unique Mechanistic Features Compared with Other Alkylating Agents , 2008, Clinical Cancer Research.

[85]  Martin Dreyling,et al.  A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. , 2006, Blood.

[86]  P. Dreger,et al.  Controversies in lymphoma: the role of hematopoietic cell transplantation for mantle cell lymphoma and peripheral T cell lymphoma. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[87]  A. Nademanee,et al.  Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[88]  Alessandro Corso,et al.  Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. , 2007, The New England journal of medicine.

[89]  R. Fisher,et al.  A Multi Center Trial of hyperCVAD+Rituxan in Patients with Newly Diagnosed Mantle Cell Lymphoma. , 2007 .

[90]  R. Advani,et al.  Phase II Study of R-CHOP Followed by 90Y-Ibritumomab Tiuxetan in Untreated Mantle Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499. , 2007 .

[91]  E. Campo,et al.  Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics , 2007, Nature Reviews Cancer.

[92]  M. Maris,et al.  Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. , 2007, Blood.

[93]  D. Straus.  How I treat mantle cell lymphoma. , 2007, Journal of oncology practice.

[94]  R. Fanin,et al.  Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome , 2007, Leukemia.

[95]  E. Giné,et al.  Leukemic involvement is a common feature in mantle cell lymphoma , 2007, Cancer.

[96]  G. Schwarzer,et al.  Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. , 2007, Journal of the National Cancer Institute.

[97]  L. Staudt,et al.  Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[98]  D. Catovsky,et al.  Cytogenetic abnormalities additional to t(11;14) correlate with clinical features in leukaemic presentation of mantle cell lymphoma, and may influence prognosis: a study of 60 cases by FISH , 2007, British journal of haematology.

[99]  J. Cayuela,et al.  Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data , 2007, Leukemia.

[100]  Andrew Lister,et al.  Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications--a study from the Lunenburg Lymphoma Biomarker Consortium. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[101]  T. Molina,et al.  Improved reliability of lymphoma diagnostics via PCR-based clonality testing: — Report of the BIOMED-2 Concerted Action BHM4-CT98-3936 , 2007, Leukemia.

[102]  D. Verhelle,et al.  Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. , 2007, Cancer research.

[103]  S. Fernández de Mattos,et al.  Rituximab, gemcitabine and oxaliplatin: An effective regimen in patients with refractory and relapsing mantle cell lymphoma , 2007, Leukemia & lymphoma.

[104]  W. Hiddemann,et al.  High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG) , 2007, Leukemia & lymphoma.

[105]  B. Coiffier,et al.  Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[106]  N. Schmitz,et al.  Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome. , 2007, Haematologica.

[107]  W. Hiddemann,et al.  Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a pros , 2006, Blood.

[108]  M. Boccadoro,et al.  Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[109]  J. Leonard,et al.  Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[110]  E. Hoster,et al.  Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas , 2006, Cancer.

[111]  C. Jones,et al.  Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[112]  S. Jagannath,et al.  Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. , 2006, Blood.

[113]  A. Tulpule,et al.  A phase II, multicenter study of bendamustine HCl plus rituximab in relapsed indolent B-cell and mantle-cell non-Hodgkin's lymphoma (NHL). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[114]  G. Georgakis,et al.  The mTOR inhibitor CCI-779 (temsirolimus) downregulates p21 and induces cell cycle arrest and autophagy in mantle cell lymphoma (MCL). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[115]  D. Trisciuoglio,et al.  Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus. , 2006, Cancer research.

[116]  P. Dubus,et al.  Blastoid and common variants of mantle cell lymphoma exhibit distinct immunophenotypic and interphase FISH features , 2006, Histopathology.

[117]  M. Bernard,et al.  Rituximab and DHAP followed by intensive therapy with autologous stem-cell transplantation as first-line therapy for mantle cell lymphoma. , 2006, Haematologica.

[118]  E. Campo,et al.  The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. , 2006, Blood.

[119]  D. Niederwieser,et al.  Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin’s lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19) , 2006, Journal of Cancer Research and Clinical Oncology.

[120]  W. Klapper,et al.  Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network , 2005, British journal of haematology.

[121]  Michael L. Wang,et al.  High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[122]  Michael E. Williams,et al.  Biology and therapy of mantle cell lymphoma , 2005, Current opinion in oncology.

[123]  R. Fonseca,et al.  Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[124]  A. Hagemeijer,et al.  Activity and safety of combined rituximab with chlorambucil in patients with mantle cell lymphoma , 2005, British journal of haematology.

[125]  M. Hansmann,et al.  Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[126]  E. Shpall,et al.  Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[127]  E. Hoster,et al.  Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the Germa , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[128]  M. Ghielmini,et al.  Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[129]  E. Hoster,et al.  Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. , 2004, Blood.

[130]  D. Gonzalez,et al.  Incomplete DJH rearrangements. , 2005, Methods in molecular medicine.

[131]  M. Maris,et al.  Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. , 2004, Blood.

[132]  D. Niederwieser,et al.  Results of a Prospective Randomised Open Label Phase III Study Comparing Rituximab Plus Mitoxantrone, Chlorambucile, Prednisolone Chemotherapy (R-MCP) Versus MCP Alone in Untreated Advanced Indolent Non-Hodgkin’s Lymphoma (NHL) and Mantle-Cell-Lymphoma (MCL). , 2004 .

[133]  R. Pazdur,et al.  Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[134]  A. Ganser,et al.  Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[135]  D. Catovsky,et al.  The Leukemic Presentation of Mantle-cell Lymphoma: Disease Features and Prognostic Factors in 58 Patients , 2004, Leukemia & lymphoma.

[136]  G. Salles,et al.  CHOP and DHAP plus rituximab followed by autologous stem cell transplantation (ASCT) in mantle cell lymphoma (MCL): A pilot study from the GELA. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[137]  J. Chan,et al.  Consistent Immunostaining for Cyclin D1 Can Be Achieved on a Routine Basis Using a Newly Available Rabbit Monoclonal Antibody , 2004, The American journal of surgical pathology.

[138]  M. Bjornsti,et al.  The tor pathway: a target for cancer therapy , 2004, Nature Reviews Cancer.

[139]  M. Boccadoro,et al.  Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[140]  J. Connors,et al.  Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[141]  A. Delmer,et al.  Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: an update of a prospective study. , 2004, Haematologica.

[142]  R. Champlin,et al.  Long‐term follow‐up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission , 2003, Cancer.

[143]  P. Mclaughlin,et al.  Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[144]  M Hummel,et al.  Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936 , 2003, Leukemia.

[145]  Mitchell R. Smith.  Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance , 2003, Oncogene.

[146]  R. Gascoyne,et al.  Limited-stage mantle-cell lymphoma. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[147]  K. Franssila,et al.  Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant , 2003, European journal of haematology.

[148]  T. Barbui,et al.  Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). , 2003, Blood.

[149]  L. Pham,et al.  Inhibition of Constitutive NF-κB Activation in Mantle Cell Lymphoma B Cells Leads to Induction of Cell Cycle Arrest and Apoptosis1 , 2003, The Journal of Immunology.

[150]  D. Catovsky,et al.  A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. , 2003, Blood.

[151]  J. Gabert,et al.  Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects , 2003, Leukemia.

[152]  D. Weisenburger,et al.  Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries , 2003, British journal of haematology.

[153]  L. Staudt,et al.  The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. , 2003, Cancer cell.

[154]  M. Herold,et al.  Randomized phase III study for the treatment of advanced indolent non-Hodgkin's lymphomas (NHL) and mantle cell lymphoma: chemotherapy versus chemotherapy plus rituximab , 2003, Annals of Hematology.

[155]  N. Schmitz,et al.  Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. , 2002, Blood.

[156]  A Orfao,et al.  Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation , 2002, Leukemia.

[157]  K. Franssila,et al.  Ki‐67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma , 2002, European journal of haematology.

[158]  S. A. Bush,et al.  High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. , 2002, Blood.

[159]  R. Bouabdallah,et al.  Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study , 2002, Leukemia.

[160]  J. Gribben,et al.  Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[161]  C. Kittas,et al.  The splenic form of mantle cell lymphoma , 2002, European journal of haematology.

[162]  P. de Nully Brown,et al.  A Danish population-based analysis of 105 mantle cell lymphoma patients: incidences, clinical features, response, survival and prognostic factors. , 2002, European journal of cancer.

[163]  B. Branger,et al.  Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype , 2001, Leukemia.

[164]  J. Leonard,et al.  Biology and management of mantle cell lymphoma , 2001, Current opinion in oncology.

[165]  A. Órfão,et al.  Minimal residual disease in leukaemia patients. , 2001, The Lancet. Oncology.

[166]  S. Johnson,et al.  Nucleoside analogues in the treatment of haematological malignancies , 2001, Expert opinion on pharmacotherapy.

[167]  A. Zelenetz,et al.  Cyclophosphamide/Fludarabine (CF) is Active in the Treatment of Mantle Cell Lymphoma , 2001, Leukemia & lymphoma.

[168]  W. Chan,et al.  Autologous hematopoietic stem cell transplantation for mantle cell lymphoma. , 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[169]  G Muller,et al.  Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. , 2000, Blood.

[170]  I. Buño,et al.  Diagnostic utility of fluorescence in situ hybridization in mantle‐cell lymphoma , 2000, British journal of haematology.

[171]  C. V. D. Schoot,et al.  Application of germline IGH probes in real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia , 2000, Leukemia.

[172]  W. Chan,et al.  Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group , 2000, American journal of hematology.

[173]  M. Seto,et al.  Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma. , 2000, Blood.

[174]  M Chilosi,et al.  Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. , 2000, Blood.

[175]  V. Diehl,et al.  Brief Report Dexa-BEAM: An Effective Regimen for Cytoreduction Prior to High-Dose Chemotherapy with Autologous Stem Cell Support for Patients with Relapsed/Refractory Mantle-Cell Lymphema , 2000 .

[176]  H. Kantarjian,et al.  Untreated Aggressive Mantle Cell Lymphoma: Results with Intensive Chemotherapy without Stem Cell Transplant in Elderly Patients , 2000, Leukemia & lymphoma.

[177]  V. Diehl,et al.  Dexa-BEAM: an effective regimen for cytoreduction prior to high-dose chemotherapy with autologous stem cell support for patients with relapsed/refractory mantle-cell lymphoma. , 2000, Leukemia and Lymphoma.

[178]  A. Pileri,et al.  Clinical relevance of minimal residual disease monitoring in non-Hodgkin’s lymphomas: a critical reappraisal of molecular strategies , 1999, Leukemia.

[179]  A. López-Guillermo,et al.  Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. , 1999, Blood.

[180]  H. Kantarjian,et al.  Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[181]  P. Moreau,et al.  High-dose therapy with stem cell transplantation for mantle cell lymphoma: results and prognostic factors, a single center experience , 1998, Bone Marrow Transplantation.

[182]  E. Campo,et al.  Blastic variant of mantle cell lymphoma shows a heterogenous pattern of somatic mutations of the rearranged immunoglobulin heavy chain variable genes , 1998, British journal of haematology.

[183]  G. Salles,et al.  Mantle cell lymphoma: a retrospective study of 121 cases , 1998, Leukemia.

[184]  M. Tiemann,et al.  Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[185]  K. Franssila,et al.  Mantle cell lymphoma: clinical features, treatment and prognosis of 94 patients. , 1998, European journal of cancer.

[186]  A. López-Guillermo,et al.  Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. , 1998, Cancer.

[187]  J. Gribben,et al.  High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[188]  J. Gribben,et al.  Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease. , 1997, Blood.

[189]  W. Benedict,et al.  Mantle cell lymphoma: correlation of clinical outcome and biologic features with three histologic variants. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[190]  G. Brittinger,et al.  Mantle cell lymphoma: diagnostic criteria, clinical aspects and therapeutic problems. , 1997, Leukemia.

[191]  R. Gascoyne,et al.  Mantle cell lymphoma: a clinicopathologic study of 80 cases. , 1997, Blood.

[192]  G. Peters,et al.  Preclinical combination therapy with gemcitabine and mechanisms of resistance. , 1996, Seminars in oncology.

[193]  W Hiddemann,et al.  Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group. , 1996, Leukemia.

[194]  F. Bosch,et al.  p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. , 1996, Blood.

[195]  A. Hagenbeek,et al.  Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[196]  D C Louie,et al.  p53 overexpression as a marker of poor prognosis in mantle cell lymphomas with t(11;14)(q13;q32). , 1995, Blood.

[197]  F. Cavalli,et al.  Patterns of survival in mantle cell lymphoma. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

[198]  H. Stein,et al.  Mantle cell (previously centrocytic) lymphomas express VH genes with no or very little somatic mutations like the physiologic cells of the follicle mantle. , 1994, Blood.

[199]  M. Engelhard,et al.  Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: Anthracycline does not improve the prognosis , 1989, Hematological oncology.

[200]  K. Lennert,et al.  Growth fractions in malignant non‐Hodgkin's lymphomas (NHL) as determined in situ with the monoclonal antibody Ki‐67 , 1984, Hematological oncology.

[201]  D. Weisenburger,et al.  Mantle‐zone lymphoma: A follicular variant of intermediate lymphocytic lymphoma , 1982, Cancer.

[202]  S Kamen,et al.  The task force. , 1976, Journal of hospital dental practice.

[203]  M. Hartmann,et al.  Investigation of cross-link formation in DNA by the alkylating cytostatic IMET 3106, 3393 and 3943. , 1972, Biochimica et biophysica acta.